Investigation of DNA medication passport for antidepressants in primary care.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27432

Enrollment

280

Registered

2020-07-29

Start date

2023-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate depression and anxiety disorders

Interventions

farmacogenetica bepaling voor aanvang behandeling met antidepressivum

Other intervention

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: · =18 jaar · eerste voorschrift N06A geneesmiddel (geen N06A geneesmiddel 1 jaar voor start N06A geneesmiddel) · diagnose milde tot matige depressie of angststoornis

Exclusion criteria

Exclusion criteria: geen CYP2C19 en CYP2D6 farmacogenetica test voorhanden of aangevraagd voor einde follow-up

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is to investigate if PGx-guided treatment with antidepressants (N06A drugs) for mild to moderate depression and/or anxiety disorders is improving therapy (less stops due to inefficacy or side effects) within the first 3 months after start treatment.	—

Secondary

Measure	Time frame
The secondary objectives are: · to monitor how often dose or drug adjustments are made after the PGx test is performed for antidepressants (exclusively analysed in intervention group) · to assess the implications of the PGx tests for other drugs · to assess what the consequence of PGx-guided treatment is on the trial-and-error treatment with antidepressants (N06A drug switches), · to assess what the consequence of PGx-guided treatment is on the referral to the secondary mental health care, · to determine if the PGx-guided antidepressants treatment before start therapy is cost-effective, · and retrospective analysis of primary and secondary objectives in control group, · retrospective analysis effect CYP3A4 on preterm stops, switches antidepressants and referral secondary mental health care	—

Measure

Time frame

The secondary objectives are: · to monitor how often dose or drug adjustments are made after the PGx test is performed for antidepressants (exclusively analysed in intervention group) · to assess the implications of the PGx tests for other drugs · to assess what the consequence of PGx-guided treatment is on the trial-and-error treatment with antidepressants (N06A drug switches), · to assess what the consequence of PGx-guided treatment is on the referral to the secondary mental health care, · to determine if the PGx-guided antidepressants treatment before start therapy is cost-effective, · and retrospective analysis of primary and secondary objectives in control group, · retrospective analysis effect CYP3A4 on preterm stops, switches antidepressants and referral secondary mental health care

—

Contacts

Public ContactM. Matic

Erasmus University Medical Center

m.matic@erasmusmc.nl0107038775

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)